The story of Viagra, initially marketed by copyright, presents a intricate case study for investors considering the pharmaceutical sector. Despite its early success and impact of billions in revenue , the exclusivity end has opened the door for alternative medications, greatly diminishing profit opportunities. This shift raises doubts about the con